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Oxypurinol Therapy for
ongestive Heart Failure) Trial
Question of Dose
e read the OPT-CHF (Oxypurinol Therapy for Congestive
eart Failure) study results with interest (1). We agree with the
uthors’ comments regarding the possible reasons oxypurinol did
ot lead to clinical benefits. However, the issue of dose needs to be
mphasized further, as the urate fall from baseline with 600 mg
xypurinol in the OPT-CHF study was 26% (2.1 mg/dl [0.12
mol/l]). Our group has previously demonstrated that with
llopurinol 300 mg, a urate fall of 44% (3.0 mg/dl [0.18 mmol/l])
an be achieved; with allopurinol 600 mg, we achieved a mean
rate fall of 61% from baseline (4.2 mg/dl [0.25 mmol/l]) (2).
rucially, in this head-to-head comparison, there was a steep
ose-response curve between the dose of allopurinol and its
eneficial vascular effects (2). This dose-response was also seen in
n observational study of heart failure patients, looking at 100 mg
ersus 300 mg allopurinol (3).
These observations and the degree of urate lowering seen in the
PT-CHF study suggest that the dose of oxypurinol used was
ell below the optimum dose. In fact, at the Arthritis Advisory
ommittee Meeting of the Food and Drug Administration (FDA)
n June 2004, data from the bioequivalence AAI-US-175 study
howed that 600 mg oxypurinol had a relative bioavailability
quivalent to 81 mg allopurinol (4). That is less than the usual
tarting dose of 100 mg and 10% of the maximal FDA-allowed
ose of 800 mg.
In addition, clinical outcomes in a 6-month trial may be more
etermined by changes in volume status rather than by improve-
ents in mechanoenergetic uncoupling, left ventricular remodel-
ng, and endothelial function, which would require a longer
uration of treatment to change clinical end points, especially in an
utcome trial with only 400 patients. Despite these limitations,
xypurinol did appear to benefit high-risk patients with raised
rate levels, a finding that underscores the need for larger studies
sing larger doses.
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oronary Angiography:
atheter Based or Computed
omography Based
read with interest the paper by Meijboom et al. (1) relating to
iagnostic accuracy of 64-slice computed tomographic coronary
ngiography (CTA) and the editorial comment on the limitations
f CTA by Nissen (2).
Bluemke et al. (3), in a scientific statement on noninvasive
oronary artery imaging, remind us that CTA gives one no option
or immediate intervention, does not serve as the only basis for
oronary artery bypass grafting (CABG), has no outcome analyses,
as angiographic comparisons with small groups pre-selected to
ndergo both procedures, and has lower spatial resolution com-
ared to catheter-based coronary angiography (CBCA); in addi-
ion, motion and other artifacts may result in false-negative and
alse-positive results with CTA, and continuous visualization of
he coronaries with CTA is not possible at present on patients with
trial fibrillation or frequent ectopy.
Further limitations as outlined by Nissen (2) are as follows:
hen CTA is used to visualize the coronary arteries, calcification
f the coronaries can cause false-negative and false-positive results,
tents make visualization of the coronary lumen difficult, and the
redominant risk of CTA is radiation exposure. However, I am
old by CTA advocates that radiation reduction strategies such as
ube modulation or prospectively ECG-triggered acquisitions are
n the horizon (4).
I have no doubt that CTA will become a useful, but limited,
iagnostic imaging device for coronary artery assessment. How-
ver, I would like to point out some of the positive values of CBCA
ince it has been and remains the standard of reference for coronary
oninvasive imaging techniques.
CBCA provides assessment about stenosis percent narrowing,
ocation, morphology, and condition of the distal vessel, stenosis
